STAAR SURGICAL (STAA)
Health Care · Ophthalmic medical devices / refractive surgery · NASDAQ
STAAR Surgical designs and manufactures implantable collamer lenses (ICLs) for refractive vision correction, offering reversible alternatives to corneal refractive surgery.
What STAAR SURGICAL does
STAAR Surgical designs, develops, manufactures, and sells implantable collamer lenses (ICLs) for refractive vision correction and related delivery systems. The company's ICLs are phakic lenses made from Collamer, a proprietary collagen copolymer material, which are implanted into the eye without removing the natural crystalline lens. STAAR markets its ICLs under the EVO family for myopia correction, including the newer EVO Viva with extended depth of focus for presbyopia treatment, as well as Visian ICL for hyperopia correction, with toric versions available to address astigmatism. Approximately 100% of revenue is generated from ICL sales globally.
Themes: ["Refractive vision correction / refractive surgery"]
Fundamentals
- Price$27.97 as of 2026-07-09 close
- Market cap$1.4B as of 2026-07-10
- 1-year return+63.2% as of 2026-07-09 close
- Net margin-7.2% as of 2026-07-10
- Gross margin+76.9% as of 2026-07-10
- ROE-6.1% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+4.0% as of 2026-07-10
- Revenue CAGR (3y)+0.0% SEC XBRL
- Beta1.23 as of 2026-07-10
Key risks (from latest filing)
["Regulatory and approval risks for new lens designs and geographic market expansion, as ICLs require FDA and international regulatory clearance before commercialization."]
Competitors & peers
- Alcon
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.